GW Pharmaceuticals Plc (GWPH)

115.31
1.96 1.67
NASDAQ : Health Technology
Prev Close 117.27
Open 120.01
Day Low/High 113.65 / 121.50
52 Wk Low/High 92.65 / 143.37
Volume 889.84K
Avg Volume 379.70K
Exchange NASDAQ
Shares Outstanding 25.30M
Market Cap 3.35B
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex® In U.S.

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex® In U.S.

- Previous License Agreement with Otsuka Terminated -

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

Party leaders will have to work toward merging the two versions of tax reform into one final bill.

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)

From tax cuts to the Flynn fallout, Jim Cramer says investors have to be covered.

Enjoy the Holiday Trading While It Lasts

Enjoy the Holiday Trading While It Lasts

Market momentum goes on a rampage.

GW Pharmaceuticals And U.S. Subsidiary Greenwich Biosciences To Present Epidiolex® (cannabidiol) Data And Educational Programs At The American Epilepsy Society Annual Meeting

GW Pharmaceuticals And U.S. Subsidiary Greenwich Biosciences To Present Epidiolex® (cannabidiol) Data And Educational Programs At The American Epilepsy Society Annual Meeting

Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program

Energy Sector Stirs a Lot of Heat

A continued rise isn't the best thing.

Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers

Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers

The Emeryville, Calif.-based firm said its first Phase 3 study of ZX008 in Dravet syndrome achieved its primary endpoint. Dravet syndrome is a form of epilepsy.

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Jim Cramer is bearish on Iconix Brands, Kinder Morgan, Snap and GW Pharmaceuticals.

TheStreet Quant Rating: D (Sell)